All News

#ClinicalPearl Joint clinic btwn ophthalmology & #rheumatology helps make dx & Rx work. #ACRBest #ACR21 see work up of inflammatory eyes disease. All are allowed one acute ant uveitis- ? dogma maybe work up all. 6S117 https://t.co/Wwdv3N66HS
Janet Pope Janetbirdope ( View Tweet)
#ACR21 Abst#0290: Ever wonder about other predictors of mortality in pts w/ RA-Lung Disease besides ILD (OR 2.3) or older age? ⭐︎ ↑ mortality associated w/ pleural effusions (OR 3.3) AND, notably... ⭐︎MTX use was protective (OR 0.4)!!! @RheumNow https://t.co/KKRkQVY2pf https://t.co/JsU2Rqzi6R

Links:

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
This study looked into the prevalence of subclinical atherosclerosis in #rheumatoidarthritis pts w/n 5 yrs of dx using carotid US. 📌vs. controls, RA pts had ⬆ CPs, cIMT ❗Screen RA pts for CV risk early on in their diagnosis @RheumNow #ACR21 abs0271 https://t.co/btU6IcM3xb
sheila RHEUMarampa ( View Tweet)
ASAS-PerSpA worldwide study: axSpA most common SpA from in family hx. Except in Middle Eastern/N. African pts, a FH of axSpA associated w/ +HLA-B27 in axSpA pts. PsO and IBD FH more likely -HLA-B27 . FH of ReA rare. Abs 0368 #ACR21 #RheumNow @RheumNow https://t.co/iHBccAcvLi https://t.co/FCoyVg3MGw

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
#ACR21 Abst#0293 RA patients with lung disease have increased rates of SSc-specific autoantibodies compared to RA w/o lung disease. ▶️ Suggests we may need to investigate further into overlap phenotype in RA-ILD @Rheumnow https://t.co/04FFuBUKmA https://t.co/A83kaie2gr

Links:

Eric Dein ericdeinmd ( View Tweet)
#ClinicalPearl. ‘my eye hurts-what’s going on!’ Dr Palestine says Ophthalmologists don’t agree on uveitis naming/ethology & worse - Rheums & eye specialists don’t speak language. Need to know infections are r/o (syphillis, CXR) & if active uveitis to ⬆️Rx #ACR21 @RheumNow https://t.co/7LkhJnUKXK
Janet Pope Janetbirdope ( View Tweet)
We should aim for early treatment and good retention in ax-SpA to prevent structural evolution. >12 months of TNFi treatment in the previous 2 years associated w/ ⬇️ radiographic progression of SIJ in r- and nr-axSpA in GESPIC, #Abst0174 @RheumNow #ACR21 https://t.co/2V1q4dUwFO https://t.co/lxQU4zAP1I

Links:

Aurelie Najm AurelieRheumo ( View Tweet)

Retrospective French study found adding JAKi may be helpful in refractory AOSD. No complete response noted and no beneficial effect as monotherapy. Possible difference between JAKi? Abs 0195 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/J8kLJpJ39o https://t.co/aVsfCQ8CyV

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Our latest article on outcomes of patients with vasculitis and PMR and COVID-19 published in @TheLancetRheum . @rheum_covid project with co-leads @SattuiSEMD and @EBRheum . https://t.co/8NTAafdYRA

Links:

Richard Conway RichardPAConway ( View Tweet)

#Fatigue is common in pts w/ #PsA- what is the impact on short-term disability? Study of ~1200 pts finds greater annual short-term disability in pts with PsA & fatigue than w/o fatigue. Impact on QoL, work & socioeconomic costs. @RheumNow #ACR21 Abs#0239 https://t.co/9yNBOovm2L https://t.co/l4tn0TSld1

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
📌Pre-Test Probability in GCA ESR/CRP can be normal: ~10% of pts at diagnosis -20-40% at time or relapse #ACR21 #ACRAmbassador #RheumTwitter https://t.co/kenaD31pYa
Nina Couette RheumDr_Nina ( View Tweet)
Machine learning predicted lupus nephritis in #SLE patients in real world data #ACR21 @RheumNow #abst0324 https://t.co/67HBT7F2GO
Bella Mehta bella_mehta ( View Tweet)
Dr Doliner @zach_wallace_md on ILD in AAV. ILD in 13% - of which 76% fibrotic. UIP most common. Most MPO+, but also rarely seen with PR3+. 47% ⬆️ risk of death. Abstr#0430 #ACR21 @RheumNow https://t.co/6MnxqW92bz
Richard Conway RichardPAConway ( View Tweet)
Dr Preger report 9 novel aminoacyl tRNA synthetases in IIM patients. May these allow us to spare more patients biopsy? Abstr#0001 #ACR21 @RheumNow https://t.co/ikNXCEOeuj
Richard Conway RichardPAConway ( View Tweet)
Don't wait! DR. Petri wants us to change paradigm of how we treat aggressive lupus nephritis: early, aggressive, and multimodal. Does not matter if you add on VCS or BLMB, just don't treat LN with MMF monotherapy. #ACR21 #GreatDebate @rheumnow https://t.co/ebSiic095h
TheDaoIndex KDAO2011 ( View Tweet)
#Flu vaccine coverage remains low in patients with #rheumatoidarthritis. Results from @earlyarthritis Abs#0141 https://t.co/DoZl5xyq2Q How can we increase vaccine uptake in our patients? @RheumNow https://t.co/nldA63EcVW

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
#ACR2021 Remember, one reason belimumab is so safe is that it does not completely deplete B cells. Particularly important in times of COVID19. Dr. Petri #GreatDebate @RheumNow

Pedro Castillo _Castillo_Pedro ( View Tweet)

Dr O'Brien on co-existent AAV and RA. Not something I'm used to seeing, but maybe we need to think about it more? 25 cases with RA+AAV, 52 with RA + ANCA but no AAV, not sure what the denominator is here though. Abstr#0428 #ACR21 @RheumNow @profgayecunnane https://t.co/fN3BRpc7UJ
Richard Conway RichardPAConway ( View Tweet)
Cluster analysis in axSpA pts classified 2 groups (predominantly axial vs peripheral dz) and showed lower TNFi drug survival rates in those with prominent extra-axial manifestations. Abs 0365 #ACR21 #RheumNow @RheumNow https://t.co/ArgQ7mNqeD https://t.co/XqF7rPneMV

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
🔥 Ready for the next level of imaging? The radio-labelled tracer binding to integrin αvβ3 99mTc-maraciclatide is able to detect hypervascularization in RA joints and correlates w/ PDUS findings ⭐️ Sens 78% ⭐️ See 91% Fancy, yet more invasive than US! #Abst0174 @RheumNow #ACR21 https://t.co/eCOxjJsERh
Aurelie Najm AurelieRheumo ( View Tweet)
×